| 000 | 01887 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516121700.0 | ||
| 264 | 0 | _c20131119 | |
| 008 | 201311s 0 0 eng d | ||
| 022 | _a1432-1041 | ||
| 024 | 7 |
_a10.1007/s00228-012-1429-9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAzuma, Junichi | |
| 245 | 0 | 0 |
_aNAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. _h[electronic resource] |
| 260 |
_bEuropean journal of clinical pharmacology _cMay 2013 |
||
| 300 |
_a1091-101 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntitubercular Agents _xadverse effects |
| 650 | 0 | 4 |
_aArylamine N-Acetyltransferase _xgenetics |
| 650 | 0 | 4 |
_aAsian People _xgenetics |
| 650 | 0 | 4 |
_aChemical and Drug Induced Liver Injury _xgenetics |
| 650 | 0 | 4 |
_aGenetic Predisposition to Disease _xgenetics |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoniazid _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPrecision Medicine _xmethods |
| 650 | 0 | 4 | _aTreatment Failure |
| 650 | 0 | 4 |
_aTuberculosis _xdrug therapy |
| 700 | 1 | _aOhno, Masako | |
| 700 | 1 | _aKubota, Ryuji | |
| 700 | 1 | _aYokota, Soichiro | |
| 700 | 1 | _aNagai, Takayuki | |
| 700 | 1 | _aTsuyuguchi, Kazunari | |
| 700 | 1 | _aOkuda, Yasuhisa | |
| 700 | 1 | _aTakashima, Tetsuya | |
| 700 | 1 | _aKamimura, Sayaka | |
| 700 | 1 | _aFujio, Yasushi | |
| 700 | 1 | _aKawase, Ichiro | |
| 773 | 0 |
_tEuropean journal of clinical pharmacology _gvol. 69 _gno. 5 _gp. 1091-101 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00228-012-1429-9 _zAvailable from publisher's website |
| 999 |
_c22262254 _d22262254 |
||